- Home
- EEA vs LUNG Comparison
EEA vs LUNG Comparison
Compare EEA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- LUNG
- Stock Information
- Founded
- EEA 1986
- LUNG 1995
- Country
- EEA Germany
- LUNG United States
- Employees
- EEA N/A
- LUNG N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- LUNG Industrial Specialties
- Sector
- EEA Finance
- LUNG Health Care
- Exchange
- EEA Nasdaq
- LUNG Nasdaq
- Market Cap
- EEA 67.9M
- LUNG 65.6M
- IPO Year
- EEA N/A
- LUNG 2020
- Fundamental
- Price
- EEA $10.93
- LUNG $1.78
- Analyst Decision
- EEA
- LUNG Buy
- Analyst Count
- EEA 0
- LUNG 7
- Target Price
- EEA N/A
- LUNG $7.66
- AVG Volume (30 Days)
- EEA 9.2K
- LUNG 317.4K
- Earning Date
- EEA 01-01-0001
- LUNG 10-29-2025
- Dividend Yield
- EEA 1.92%
- LUNG N/A
- EPS Growth
- EEA N/A
- LUNG N/A
- EPS
- EEA N/A
- LUNG N/A
- Revenue
- EEA N/A
- LUNG $90,549,000.00
- Revenue This Year
- EEA N/A
- LUNG $10.30
- Revenue Next Year
- EEA N/A
- LUNG $14.72
- P/E Ratio
- EEA N/A
- LUNG N/A
- Revenue Growth
- EEA N/A
- LUNG 18.24
- 52 Week Low
- EEA $7.45
- LUNG $1.47
- 52 Week High
- EEA $9.26
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- EEA 60.14
- LUNG 49.33
- Support Level
- EEA $10.80
- LUNG $1.71
- Resistance Level
- EEA $11.03
- LUNG $1.94
- Average True Range (ATR)
- EEA 0.12
- LUNG 0.11
- MACD
- EEA 0.01
- LUNG 0.02
- Stochastic Oscillator
- EEA 69.14
- LUNG 44.03
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.